Global Medical REIT (NYSE:GMRE) Issues FY 2026 Earnings Guidance

Global Medical REIT (NYSE:GMRE) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.300-4.450 for the period, compared to the consensus estimate of 1.740. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GMRE shares. Wall Street Zen downgraded shares of Global Medical REIT from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Weiss Ratings upgraded shares of Global Medical REIT from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, January 21st. Finally, Robert W. Baird cut their price objective on Global Medical REIT from $45.00 to $41.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Global Medical REIT Price Performance

NYSE:GMRE opened at $35.96 on Friday. Global Medical REIT has a 12-month low of $29.05 and a 12-month high of $45.75. The firm has a market cap of $482.22 million, a price-to-earnings ratio of -143.84 and a beta of 1.18. The company’s 50-day moving average is $35.20 and its two-hundred day moving average is $34.37. The company has a current ratio of 0.52, a quick ratio of 0.52 and a debt-to-equity ratio of 1.65.

Global Medical REIT Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 19th were given a dividend of $0.75 per share. The ex-dividend date was Friday, December 19th. This represents a $3.00 dividend on an annualized basis and a yield of 8.3%. Global Medical REIT’s dividend payout ratio (DPR) is -1,200.00%.

Institutional Investors Weigh In On Global Medical REIT

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP grew its position in shares of Global Medical REIT by 0.8% in the fourth quarter. Marshall Wace LLP now owns 38,244 shares of the company’s stock valued at $1,290,000 after purchasing an additional 308 shares during the period. Daiwa Securities Group Inc. grew its holdings in Global Medical REIT by 7.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 4,827 shares of the company’s stock valued at $163,000 after buying an additional 332 shares during the period. Caitong International Asset Management Co. Ltd grew its holdings in Global Medical REIT by 1,001.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 793 shares of the company’s stock valued at $27,000 after buying an additional 721 shares during the period. Virtus Advisers LLC increased its stake in shares of Global Medical REIT by 46.5% during the 4th quarter. Virtus Advisers LLC now owns 2,418 shares of the company’s stock valued at $82,000 after acquiring an additional 768 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Global Medical REIT by 5.9% during the 4th quarter. Wells Fargo & Company MN now owns 26,646 shares of the company’s stock worth $899,000 after acquiring an additional 1,490 shares during the period. Institutional investors and hedge funds own 57.52% of the company’s stock.

About Global Medical REIT

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.